CJC-1295 with DAC Research Guide
What Is CJC-1295 with DAC?
CJC-1295 with DAC is a synthetic peptide analogue of Growth Hormone Releasing Hormone (GHRH). It was developed through peptide engineering to interact with growth hormone signalling pathways while incorporating a Drug Affinity Complex (DAC), a modification designed to extend the peptide's duration of activity.
Within peptide research, CJC-1295 with DAC has become one of the most recognised compounds in the GHRH analogue category. Its unique structure and long history within scientific literature have made it a significant subject of interest among researchers studying endocrine function and hormone signalling.
Due to the addition of the Drug Affinity Complex, CJC-1295 with DAC is considered distinct from CJC-1295 (No DAC), despite sharing a common origin.
Understanding How CJC-1295 with DAC Works
CJC-1295 with DAC functions as a Growth Hormone Releasing Hormone (GHRH) analogue.
Researchers have investigated how GHRH analogues interact with receptors located within the anterior pituitary gland, influencing signalling pathways involved in endogenous growth hormone release.
The addition of the Drug Affinity Complex allows the peptide to bind to circulating albumin, a naturally occurring protein within the bloodstream. This characteristic has been a major focus of scientific research and is the primary distinction between CJC-1295 with DAC and CJC-1295 (No DAC).
Why Researchers Study CJC-1295 with DAC
CJC-1295 with DAC has been investigated across several scientific disciplines, including:
- Endocrine signalling
- Growth hormone regulation
- Hormone-receptor interactions
- Peptide engineering
- Metabolic research
- Healthy ageing research
- Cellular signalling pathways
Its unique structural characteristics and extensive scientific history continue to make it one of the most widely studied GHRH analogues.
What Does DAC Mean?
DAC stands for Drug Affinity Complex.
The Drug Affinity Complex is a structural modification designed to allow CJC-1295 to bind to albumin, a naturally occurring transport protein found within the bloodstream.
Researchers have studied this modification extensively due to its influence on the peptide's pharmacokinetic profile. The presence of DAC is the defining feature that distinguishes CJC-1295 with DAC from Modified GRF 1-29 (CJC-1295 No DAC).
CJC-1295 with DAC vs CJC-1295 (No DAC)
Although the names are similar, these compounds are structurally distinct.
CJC-1295 with DAC
A GHRH analogue containing a Drug Affinity Complex designed to prolong activity through albumin binding.
CJC-1295 (No DAC)
Also known as Modified GRF 1-29, a GHRH analogue that does not contain a Drug Affinity Complex.
Both compounds are commonly studied within growth hormone-related research but possess different structural characteristics.
CJC-1295 with DAC Compared to Other Research Peptides
CJC-1295 with DAC
A synthetic GHRH analogue incorporating a Drug Affinity Complex (DAC).
Tesamorelin
A synthetic GHRH analogue with a distinct structure and developmental background.
Ipamorelin
A Growth Hormone Releasing Peptide (GHRP) that acts primarily through the ghrelin receptor pathway.
CJC-1295 & Ipamorelin
A commonly discussed combination that involves multiple growth hormone-related signalling pathways.
Each compound possesses a unique structure and may be investigated for different scientific purposes.
Product Specifications
Compound: CJC-1295 with DAC
Quantity: 5mg
Form: Lyophilised powder
Appearance: White to off-white powder
Storage: Store refrigerated upon receipt
Testing: Independently batch tested
Research Classification: GHRH Analogue
Independent Batch Testing
At Platinum Peptides, transparency and quality assurance remain central to our approach.
Every batch undergoes independent third-party analytical testing to verify identity and purity before being released.
Why Batch Testing Matters
Identity Verification
Confirms that the material matches the labelled compound.
Purity Analysis
Provides confidence that the sample meets established quality standards.
Consistency
Helps ensure batch-to-batch reliability and reproducibility.
Transparency
Allows researchers to review independent analytical data before making purchasing decisions.
Certificates of Analysis are available for each batch where applicable.
Storage Information
Lyophilised peptides should be stored in a cool, dry environment and protected from excessive heat, moisture and direct sunlight.
Researchers should always review appropriate storage conditions relevant to their specific protocols and applications.
Frequently Asked Questions
What is CJC-1295 with DAC?
CJC-1295 with DAC is a synthetic Growth Hormone Releasing Hormone (GHRH) analogue that incorporates a Drug Affinity Complex (DAC).
What does DAC stand for?
DAC stands for Drug Affinity Complex, a structural modification designed to allow the peptide to bind to albumin.
Is CJC-1295 with DAC the same as Modified GRF 1-29?
No. Modified GRF 1-29 refers to CJC-1295 (No DAC), which does not contain a Drug Affinity Complex.
What is the difference between CJC-1295 with DAC and CJC-1295 (No DAC)?
The primary difference is the presence of the Drug Affinity Complex, which alters the structural and pharmacokinetic characteristics of the peptide.
What type of peptide is CJC-1295 with DAC?
It is classified as a Growth Hormone Releasing Hormone (GHRH) analogue.
Is CJC-1295 with DAC batch tested?
Yes. Platinum Peptides uses independent third-party testing to verify batch quality and purity.
How should CJC-1295 with DAC be stored?
Store in accordance with established peptide storage guidelines and maintain refrigeration where appropriate.
Related Research Compounds
Researchers interested in CJC-1295 with DAC may also wish to explore:
Important Information
This product is supplied strictly for laboratory research purposes only.
It is not intended for human consumption, therapeutic use, diagnostic use or veterinary use.
Researchers are responsible for ensuring compliance with all applicable laws, regulations and research protocols relating to the handling and use of peptide compounds.
Platinum Peptides does not provide guidance regarding dosage, administration, usage protocols or expected effects. Researchers are responsible for conducting their own independent research.